MetaCap

Stereotaxis Inc. (STXS)

NYSE: STXSHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD

0.9422-0.0678 (-6.71%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

STXS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$95.03M
EPS (TTM)
-$0.24
52-week range
0.80 – 2.86
Day range
0.9031 – 1.01
Volume / Avg
1.25M / 715.12K
Beta
—

52-week range

$0.80$2.86

STXS stock today

On Nov 20, STXS ended the session at $0.9422, shedding $0.0678 (6.71%), versus the S&P 500's 3.70% decline. At this level, STXS sits near the bottom of its 52-week range of $0.80 to $2.86: 67.1% below the high, set on Jan 15, 2026 and 17.8% above the low. STXS is down 59.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 59.4%.

Stereotaxis has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Stereotaxis

Company profile

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems.

Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
CEO
Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
Headquarters
Saint Louis, MO
Employees
131

Financial highlights

Full financials

In fiscal 2025, Stereotaxis generated $32.4 million in revenue, up 20.3% from fiscal 2024, its 2nd consecutive year of revenue growth. Stereotaxis reported a net loss of $21.6 million, compared with a loss of $24.0 million a year earlier. Gross margin was 52.7% (down from 54.2%) and operating margin -68.3%.

Stereotaxis annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$32.38M$26.92M$26.77M$28.15M$35.02M
Growth+20.28%+0.55%-4.89%-19.63%+31.51%
Net income$-21.64M$-24.05M$-20.71M$-18.29M$-10.72M
EPS (diluted)$-0.25$-0.30$-0.27$-0.26$-0.16

Analyst forecast

Forecast

Consensus (3 analysts)

none

Avg. price target

$3.00+218.40%

  • Strong buy 1
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.03 vs —

STXS news

All STXS news

Stereotaxis peers

Health Care sector
STXS peer companies
CompanyPrice% ChgMarket capCompare
HSDTSolana Company Class A1.49-10.24%$93.70Mvs STXS
VANIVivani Medical Inc.1.14+4.59%$102.83Mvs STXS
FOCLEDAP TMS S.A. ADR2.61-7.45%$123.25Mvs STXS
NRXSNeuraxis Inc.4.22-6.22%$59.90Mvs STXS
HYPRHyperfine Inc. Class A0.5465+4.27%$57.96Mvs STXS
OMOutset Medical Inc.2.81-3.44%$53.03Mvs STXS
POCIPrecision Optics Corporation Inc.4.12+1.41%$45.30Mvs STXS
ECORelectroCore Inc.4.42-8.87%$40.78Mvs STXS

Indexes, lists and sector

Stereotaxis stock FAQ

What is Stereotaxis's stock price today?

STXS last traded at $0.9422 as of Nov 20, 4:00 PM EST, down 6.71% on the day. Prices are delayed at least 15 minutes.

Does Stereotaxis pay a dividend?

No. Stereotaxis does not currently pay a regular cash dividend.

Who is Stereotaxis's CEO?

Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A. is the chief executive officer of Stereotaxis Inc., which has about 131 employees.

Has STXS ever split its stock?

Yes. The most recent STXS stock split was a 1096-for-1000 split on Nov 4, 2013, one of 2 splits on record.

What is the STXS 52-week high?

The 52-week high for STXS is $2.86 and the 52-week low is $0.80. The stock is currently 67.1% below its high.

Compare STXS